반려동물 의약품 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 반려동물별, 투여 경로별, 약물 유형별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Pet Medicine Market Summary

The global pet medicine market size was estimated at USD 14.5 billion in 2025 and is projected to reach USD 32.8 billion by 2033, growing at a CAGR of 10.9% from 2026 to 2033. The industry is growing due to rising chronic diseases in dogs and cats, expansion of vaccination and preventive care programs, innovation in veterinary therapeutics and biologics, and increasing funding for companion animal research.

A key driver for the market is rapid innovation in veterinary therapeutics and biologics that is expanding treatment options for chronic and complex diseases in companion animals. Pharmaceutical companies and veterinary research groups are introducing advanced therapies that mirror innovations seen in human medicine, which is increasing clinical adoption and improving treatment outcomes for pets. One such instance is the February 2026 approval of Merck & Co.'s NUMELVI (atinvicitinib tablets) by the FDA; this product is used for dogs suffering from allergic dermatitis. The therapy is a second-generation Janus kinase (JAK) inhibitor designed to control pruritus associated with allergic skin diseases in dogs. The product received approval from the FDA and is the first veterinary therapy in its class, providing once-daily treatment that directly targets inflammatory cytokine pathways responsible for itching and skin inflammation.

Biologic therapies are also gaining traction in pet medicine. Companies such as Zoetis are investing in monoclonal antibody research for animals. These therapies are designed to target specific disease pathways with high precision and have already been used to manage conditions such as chronic pain and inflammatory disorders in companion animals. Their mechanism of action resembles biologic treatments widely used in human medicine, which highlights the convergence of human and veterinary drug innovation. Another area of rapid advancement is regenerative medicine. Veterinary researchers are increasingly exploring stem cell therapy for pets to treat degenerative conditions such as osteoarthritis and orthopedic injuries. These therapies involve collecting and processing stem cells from the animal and reintroducing them into damaged tissues to promote healing and tissue regeneration. Veterinary clinics are testing these treatments as alternatives to invasive surgery or long-term medication in dogs and cats.

Precision medicine and immunotherapy are also emerging as high-growth areas. Research initiatives are studying targeted immune therapies and genomic approaches to treat diseases such as cancer in companion animals. These programs aim to personalize treatment strategies based on genetic or molecular disease profiles, which can improve treatment success rates and reduce adverse effects. To conclude, advances in biologics, regenerative medicine, and targeted pharmaceuticals are reshaping the pet medicine sector. These innovations are expanding the therapeutic pipeline and driving higher demand for advanced veterinary treatments.

Global Pet Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pet medicine market report based on product, pet, route of administration, distribution channel, drug type, and region.

• Pet Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Cats
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
  • Vaccines
  • Modified/ Attenuated Live
  • Inactivated (Killed)
  • Other Vaccines
  • Other Biologics
• Pharmaceuticals
  • Parasiticides
  • Anti-infectives
  • Anti-inflammatory
  • Analgesics
  • Others
• Medicated Feed Additives
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Topical
• Other Routes
• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Branded
• Generics
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• E-commerce
• Offline Retail Stores
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Animal
  • 1.2.3. Route of Administration
  • 1.2.4. Drug Type
  • 1.2.5. Distribution Channel
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3 Volume-Pricing Analysis
• 1.8. List of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Chronic Diseases In Dogs And Cats
    • 3.2.1.2. Expansion Of Vaccination And Preventive Care Programs
    • 3.2.1.3. Innovation In Veterinary Therapeutics And Biologics
    • 3.2.1.4. Increasing Funding For Companion Animal Research
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Drug Bans And Regulatory Restrictions
    • 3.2.2.2. Tariffs Increasing Veterinary Medicine Costs
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL by SWOT Analysis
• 3.4. Estimated Pet Population By Species & Key Countries, 2025
• 3.5. Pricing Analysis
• 3.6. User Perspective Analysis
• 3.7. Tariff Impact Analysis
  • 3.7.1. Sector Impact Analysis
  • 3.7.2. Geographical Impact Analysis
• 3.8. Strategic Opportunities & Risk for the Pet Medicine Sector

Chapter 4. Pet Medicine Market: By Pet Estimates & Trend Analysis

• 4.1. Pet Medicine Market, By Pet: Segment Dashboard
• 4.2. Pet Medicine Market, By Pet Movement Analysis
• 4.3. Pet Medicine Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 4.4. Dogs
  • 4.4.1. Dogs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Cats
  • 4.5.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pet Medicine Market: By Product Estimates & Trend Analysis

• 5.1. Pet Medicine Market, By Product: Segment Dashboard
• 5.2. Pet Medicine Market, By Product Movement Analysis
• 5.3. Pet Medicine Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 5.4. Biologics
  • 5.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Vaccines
    • 5.4.2.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.1.1. Modified/ Attenuated Live
        • 5.4.2.1.1.1. Modified/ Attenuated Live Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.1.2. Inactivated (Killed)
        • 5.4.2.1.2.1. Inactivated (Killed) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.1.3. Other Vaccines
        • 5.4.2.1.3.1. Other Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Other Biologics
    • 5.4.3.1. Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Pharmaceuticals
  • 5.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Parasiticides
    • 5.5.2.1. Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Anti-infectives
    • 5.5.3.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Anti-inflammatory
    • 5.5.4.1. Anti-inflammatory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Analgesics
    • 5.5.5.1. Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.6. Others
    • 5.5.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Medicated Feed Additives
  • 5.6.1. Medicated Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pet Medicine Market: By Route of Administration Estimates & Trend Analysis

• 6.1. Pet Medicine Market, By Route of Administration: Segment Dashboard
• 6.2. Pet Medicine Market, By Route of Administration Movement Analysis
• 6.3. Pet Medicine Market Estimates & Forecasts, by Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Injectable
  • 6.5.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Topical
  • 6.6.1. Topical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Other Routes
  • 6.7.1. Other Routes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pet Medicine Market: By Drug Type Estimates & Trend Analysis

• 7.1. Pet Medicine Market, By Drug Type: Segment Dashboard
• 7.2. Pet Medicine Market, By Drug Type Movement Analysis
• 7.3. Pet Medicine Market Estimates & Forecasts, by Drug Type, 2021 to 2033 (USD Million)
• 7.4. Branded
  • 7.4.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Generics
  • 7.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Pet Medicine Market: By Distribution Channel Estimates & Trend Analysis

• 8.1. Pet Medicine Market, By Distribution Channel: Segment Dashboard
• 8.2. Pet Medicine Market, By Distribution Channel Movement Analysis
• 8.3. Pet Medicine Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
• 8.4. Veterinary Hospitals & Clinics
  • 8.4.1. Veterinary Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. E-commerce
  • 8.5.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Offline Retail Stores
  • 8.6.1. Offline Retail Stores Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Others
  • 8.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Pet Medicine Market: By Regional Estimates & Trend Analysis

• 9.1. Region Market Dashboard
• 9.2. Region Market Share Analysis, 2025 & 2033
• 9.3. North America
  • 9.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.2. U.S
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Competitive Scenario
    • 9.4.8.3. Regulatory Framework
    • 9.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Competitive Scenario
    • 9.4.9.3. Regulatory Framework
    • 9.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.10. Netherlands
    • 9.4.10.1. Key Country Dynamics
    • 9.4.10.2. Competitive Scenario
    • 9.4.10.3. Regulatory Framework
    • 9.4.10.4. Netherlands Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Australia
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. South Korea
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.4. Saudi Arabia
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Competitive Scenario
    • 9.7.5.3. Regulatory Framework
    • 9.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.6. Qatar
    • 9.7.6.1. Key Country Dynamics
    • 9.7.6.2. Competitive Scenario
    • 9.7.6.3. Regulatory Framework
    • 9.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.7. Oman
    • 9.7.7.1. Key Country Dynamics
    • 9.7.7.2. Competitive Scenario
    • 9.7.7.3. Regulatory Framework
    • 9.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
  • 10.1.1. Market Leaders
  • 10.1.2. Emerging Players
• 10.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 10.3. Company Profiles
  • 10.3.1. Zoetis Inc.
    • 10.3.1.1. Participant's Overview
    • 10.3.1.2. Financial Performance
    • 10.3.1.3. Product/Service Benchmarking
    • 10.3.1.4. Strategic Initiatives
  • 10.3.2. Boehringer Ingelheim International Gmbh
    • 10.3.2.1. Participant's Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Product/Service Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. Merck & Co., Inc.
    • 10.3.3.1. Participant's Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Product/Service Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. Elanco
    • 10.3.4.1. Participant's Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Product/Service Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. Dechra Pharmaceuticals PLC
    • 10.3.5.1. Participant's Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Product/Service Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. Ceva Sante Animale
    • 10.3.6.1. Participant's Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Product/Service Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. Phibro Animal Health Corporation
    • 10.3.7.1. Participant's Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Product/Service Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Virbac
    • 10.3.8.1. Participant's Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Product/Service Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Bimeda Corporate
    • 10.3.9.1. Participant's Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Product/Service Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. Biogenesis Bago
    • 10.3.10.1. Participant's Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Product/Service Benchmarking
    • 10.3.10.4. Strategic Initiatives